treace medical concepts, inc. is a privately-funded, commercial stage company focused on bringing breakthrough technologies to the high-growth $1.1 billion us market for foot and ankle surgical products. we are committed to operating our business with the highest standards of ethical conduct. we will exceed our customers’ expectations through an innovation-driven, high-velocity approach to solving treatment and surgical problems. with our products and services, our mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for our employees and an exceptional return for our shareholders.
Company profile
Ticker
TMCI
Exchange
Website
CEO
John T. Treace
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
471052611
TMCI stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
2 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
ARS
2023 FY
Annual report to shareholders
2 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance
27 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Treace Medical Concepts Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
TMCI
Earnings call transcript
2023 Q4
27 Feb 24
TMCI
Earnings call transcript
2023 Q3
9 Nov 23
TMCI
Earnings call transcript
2023 Q2
8 Aug 23
TMCI
Earnings call transcript
2023 Q1
8 May 23
TMCI
Earnings call transcript
2022 Q4
7 Mar 23
TMCI
Earnings call transcript
2022 Q3
12 Nov 22
TMCI
Earnings call transcript
2022 Q2
13 Aug 22
TMCI
Earnings call transcript
2022 Q1
8 May 22
TMCI
Earnings call transcript
2021 Q4
4 Mar 22
TMCI
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
4
JAMES T TREACE
29 Mar 24
4
Aaron Berutti
12 Mar 24
4
Mark Hair
12 Mar 24
4
John T. Treace
12 Mar 24
4
Sean F. Scanlan
12 Mar 24
4
Scot Michael Elder
12 Mar 24
SC 13G/A
ALLIANCEBERNSTEIN L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Treace John T.
9 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.28 mm | 7.28 mm | 7.28 mm | 7.28 mm | 7.28 mm | 7.28 mm |
Cash burn (monthly) | 1.59 mm | 6.77 mm | 5.94 mm | 4.01 mm | 3.17 mm | 3.37 mm |
Cash used (since last report) | 10.81 mm | 46.18 mm | 40.50 mm | 27.36 mm | 21.63 mm | 23.00 mm |
Cash remaining | -3.54 mm | -38.91 mm | -33.23 mm | -20.08 mm | -14.35 mm | -15.72 mm |
Runway (months of cash) | -2.2 | -5.7 | -5.6 | -5.0 | -4.5 | -4.7 |
Institutional ownership, Q3 2023
62.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 123 |
Opened positions | 24 |
Closed positions | 38 |
Increased positions | 63 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 486.86 bn |
Total shares | 38.31 mm |
Total puts | 55.40 k |
Total calls | 114.30 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Alliancebernstein | 4.31 mm | $56.49 bn |
Vanguard | 4.19 mm | $54.93 bn |
BLK Blackrock | 3.46 mm | $45.33 bn |
Soleus Capital Management | 1.91 mm | $25.01 bn |
Perceptive Advisors | 1.83 mm | $24.04 bn |
William Blair Investment Management | 1.79 mm | $23.41 bn |
Emerald Advisers | 1.47 mm | $19.31 bn |
TimesSquare Capital Management | 1.43 mm | $18.79 bn |
CIBC Private Wealth | 1.38 mm | $18.14 bn |
STT State Street | 1.30 mm | $17.11 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Mar 24 | Sean F. Scanlan | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 1,396 | 0.00 | 95,424 |
10 Mar 24 | Scot Michael Elder | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 1,666 | 0.00 | 108,375 |
10 Mar 24 | Aaron Berutti | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 1,815 | 0.00 | 105,341 |
10 Mar 24 | Mark Hair | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 4,088 | 0.00 | 160,655 |
10 Mar 24 | John T. Treace | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 5,021 | 0.00 | 5,793,095 |
8 Mar 24 | Sean F. Scanlan | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 389 | 0.00 | 96,820 |
8 Mar 24 | Scot Michael Elder | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 169 | 0.00 | 110,041 |
8 Mar 24 | Aaron Berutti | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 711 | 0.00 | 107,156 |
8 Mar 24 | Mark Hair | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 1,067 | 0.00 | 164,743 |
8 Mar 24 | John T. Treace | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 2,064 | 0.00 | 5,798,116 |
Press releases
Treace to Present at Bank of America Health Care Conference
17 Apr 24
Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone
25 Mar 24
Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
2 Feb 24
Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
1 Feb 24